SURGICAL METHOD FOR TREATING THE CASES OF ABLATIO RETINAE Russian patent published in 2004 - IPC

FIELD: medicine.

SUBSTANCE: method involves carrying out epibulbar anesthesia, retrobulbar anesthesia and akinesia of orbicular muscle of the eye, vitrectomy with endovitreous illumination and substituting physiological salt solution supply via liquid-gas exchange system cannula preliminarily sutured through a pierce in sclera. Localization and area of retinal rupture is concurrently adjusted. Intravitreous stretching and smoothing of the retina is carried out by introducing perfluororganic compound into the vitreous chamber. Extraocular flexible extrascleral magnetic polymer implant fixation is carried out in retina rupture or detachment zone. Intravitreous retina defect zone is closed by introducing intravitreous flexible magnetic implant modeled to match rupture outline and sizes exceeding defect area by 20-60%. The perfluororganic compound is substituted for self-expanding air-gas mixture. The extrascleral magnetic implant of 3.5-5.0 mTesla units density is manufactured from biologically stable polymer material based on polyacrylate, vinyl polymer or silicon rubber containing uniformly distributed powder particles of permanent magnet material of samarium-cobalt system or neodymium-iron-boron. The intravitreous flexible magnetic implant has 1.0-2.0 mTesla units density and manufactured from biodegradable material. The extrascleral flexible magnetic implant is to be removed in 80-120 days after accomplishing the operation. The intravitreous flexible biodegradable magnetic implant is left on the place it has been set. The extrascleral flexible magnetic implant is introduced with its thickness being equal to 0.35-3.0 mm. The intravitreous flexible biodegradable magnetic implant is introduced with its thickness being equal to 0.15-0.25 mm. Perluoropolyester or perfluorotributyleneamine or perfluorodecaline or perfluorometylcyclohexylperidine is introduced as the perfluororganic compound in the amount of 0.65-0.85 of vitreous chamber volume. The self-expanding air-gas mixture is used with 15-25% gas by volume. Sulfahexafluoride (SF₆) or hexafluorocyclopropane (C₃F₆) or octofluorocyclobutane (C₄F₈).

EFFECT: enhanced effectiveness of surgical treatment.

5 cl